Anti-cancer star

Trametinib has demonstrated excellent efficacy in a variety of cancer types, especially malignant melanoma and non-small cell lung cancer carryingBRAF V600E or V600K mutations. As monotherapy, trametinib is approved for the treatment of patients with unresectable or metastatic melanoma harboring BRAF V600E and V600K mutations.

As a representative drugMEK1/2 inhibitor, it is reshaping the treatment landscape of advanced cancer with unique molecular intervention methods. This drug selectively binds to the ATP-binding pocket of MEK kinase, preventing ATP from catalyzing the phosphorylation of tyrosine residues, thereby effectively blocking the ERK signal transduction pathway. This precise attack significantly inhibited the abnormal proliferation signal of BRAF V600 mutant tumors, increasing the 5-year survival rate of patients with advanced malignant melanoma from less than 10% in the traditional treatment era to 38%. The combination dabrafenib treatment regimen approved by the FDA has achieved a breakthrough in achieving a median overall survival of 48 months, becoming the first regimen that allows patients with advanced melanoma the opportunity to achieve "chronic disease" management.

In recent years, clinical research has continued to expand its indication boundaries. In low-grade serous ovarian cancer combined withNF1 mutations, monotherapy increased the disease control rate to 72%; for anaplastic thyroid cancer, combination with multi-kinase inhibitors led to a tumor regression rate of 52%. It is worth noting that the pharmacokinetics show non-linear absorption characteristics. When the dose is increased from 1 mg to 2 mg, the AUC value increases by 4.3 times, which requires that clinical practice must strictly follow the dose escalation principle. The latest treatment monitoring technology, such as micro-implantable drug concentration monitoring chips, can track blood drug concentration fluctuations in real time to ensure that treatment is within the effective window of 8.3-30.5nmol/L.

Reference materials:https://go.drugbank.com/drugs/DB08911